SABR to oligometastases slows progression via immune response

Stereotactic ablative body radiation (SABR, or sometimes, SBRT) significantly slowed metastatic progression in men with three or fewer metastases (oligometastatic disease). … READ MORE …

Should SBRT be THE preferred treatment for intermediate-risk prostate cancer?

Last year, the American Society of Radiation Oncologists (ASTRO) looked at the available evidence comparing hypofractionated radiotherapy (either 60 Gy in 20 treatments or 70 Gy in 28 treatments) to standard fractionation (78 to 82 Gy in 40 to 44 treatments), and found it was at least as good in terms of oncological outcomes and toxicity. … READ MORE …

SBRT has non-inferior acute and late-term toxicity vs IMRT in two randomized clinical trials

In October 2018, the American Society of Radiation Oncologists (ASTRO) strongly endorsed moderately hypofractionated IMRT (20 or 28 treatments) for primary radiation treatment (see this link). … READ MORE …

SBRT: the optimal dose

While excellent outcomes of stereotactic body radiation therapy (SBRT) have been reported since it was first used to treat prostate cancer in 2003, the delivered doses have ranged from 35 Gy in five treatments to 40 Gy in five treatments. … READ MORE …

SBRT has excellent outcomes for intermediate-risk patients

Stereotactic body radiation therapy or SBRT (sometimes referred to as SABR or SHARP or CyberKnife) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. … READ MORE …

Updated results of 5-year SBRT trial: high cancer control, low toxicity

Meier et al. have just published updated results of a 5-year multi-institutional trial finding that stereotactic body radiation therapy (SBRT) had high rates of cancer control and low toxicity. … READ MORE …

SBRT has equivalent toxicity with 5 treatments and 12 treatments: an update

We first reported data from the results of the RTOG 0938 trial in January 2016 when they were presented at the Genitourinary Cancers Symposium in that year. These results have now been formally published, and there are some changes to the data on publication, so Allen Edel has provided an update. … READ MORE …

First randomized clinical trial of SBRT reports primary outcome

In the first trial ever to randomly assign patients to extreme hypofractionation, primary radiation therapy delivered in just seven treatments had the same effectiveness and safety as 39 treatments. … READ MORE …

Salvage SBRT after radical prostatectomy

The University of California, Los Angeles (UCLA) has announced a new clinical trial using stereotactic body radiation therapy (SBRT) for treatment of recurrent prostate cancer after failure of initial prostatectomy. … READ MORE …

Record 10-year SBRT study among low-risk patients

Alan Katz has now published the study with the longest-running follow-up of any study of external beam radiation therapy for prostate cancer among low-risk patients, in this case using SBRT. … READ MORE …

After failure of first-line radiation, both kinds of salvage brachytherapy are equally effective

A group of researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reported in 2014 (see this link) on the outcomes of 42 patients with radio-recurrent prostate cancer treated with salvage high-dose-rate brachytherapy (sHDR-BT). The results were quite good — … READ MORE …

First US randomized clinical trial of oligometastasis-directed SBRT

In a recent commentary (see this link), we saw that some clinicians are making unsubstantiated claims of cancer control from treatment of oligometastases (less than 5 detected metastases). … READ MORE …

Unwarranted conclusions about treatment of oligometastatic prostate cancer

Many patients wonder, if they just have a couple of metastases, why can’t those be “zapped” by a few quick SBRT treatments and they can’t thereby be cured of their prostate cancer? Or, even if they can’t be cured, can’t the cancer’s progression be slowed down? … READ MORE …

SBRT dose escalation

Is there an optimum treatment dose for sterotactic body radiation therapy (SBRT)? … READ MORE …

SBRT vs. standard IMRT as first-line radiation therapy for localized prostate cancer

Many readers may be interested in an article by Gina Kolata in today’s issue of The New York Times. It deals with the rising popularity of stereotactic body radiation therapy (SBRT) in the management of localized prostate cancer. … READ MORE …